Clear Street Maintains Buy on Ocular Therapeutix, Raises Price Target to $28
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Clear Street analyst Bill Maughan maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $28.
Clear Street analyst Bill Maughan maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $28.